MUMBAI, India, June 30 -- Intellectual Property India has published a patent application (202641072932 A) filed by Saveetha Institute Of Medical And Technical Sciences on June 12, 2026, for Ai-Powered Adaptive Drug Delivery System Using Real-Time Biosensor Feedback.
Inventors include Dr. Thilagavathi K; S Tharshini; and Deepak Nallaswamy Veeraiyan.
The application for the patent was published on June 26, 2026, under issue no. 26/2026.
Abstract: The present invention discloses an Al-powered adaptive drug delivery system that integrates realtime multi-analyte biosensing with machine learhing^riven closed-loop pharmacotherapy. The system comprises a wearable or semi-implantable device housing a multi-analyte electrochemical and optical biosensor array, an embedded Al inference engine utilizing Long Short-Term Memory neural networks and Deep Reinforcement Learning, and a microfluidic drug delivery module with piezoelectric micro-pumps, MEMS micro-valves, and hollow micro-needle delivery arrays. The biosensor array continuously monitors physiological biomarkers including glucose, lactic acid, and inflammatory proteins in interstitial fluid via a minimally invasive micro-needle interface. The Al engine processes real time data to autonomously determine optimal drug type, dosage volume, and delivery rate, with continuous patient-specific personalization achieved through on-device federated learning. The microfluidic module executes drug delivery with nanoliter precision and confirms accuracy via integrated flow sensors in a fully closed-loop control architecture. A multi layer safety management unit with hardware watchdog timers, pressure and thermal sensors, software anomaly detectors, and AES-256 encrypted wireless communication enables real-time physician oversight and remote intervention via a HIPAA compliant portal. The system is broadly applicable across chronic diseases including diabetes, cancer, and neurological disorders, representing a universal closed-loop precision pharmacotherapy platform designed to reduce adverse drug events, improve therapeutic outcomes, and enable effective home-based chronic disease management with continuous.
Disclaimer: Curated by HT Syndication.
